BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 30, 2024
See today's BioWorld
Home
» Deciphera gains $52M in muscle to move lead assets to next level
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Deciphera gains $52M in muscle to move lead assets to next level
June 2, 2017
By
Marie Powers
No Comments
On the eve of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Deciphera Pharmaceuticals LLC disclosed a $52 million series C financing to advance lead candidates DCC-2618 and DCC-3014 beyond phase I.
BioWorld